0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum]

      Drug Design, Development and Therapy

      Dove

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Toshida H, Funaki T, Ono K, et al. Drug Des Devel Ther. 2017;11:1871–1879 Table 3 Mean Change in Symptom Score Week Mean Change P-value Placebo VApal Dryness 1 −0.45±0.10 −0.73±0.12 0.0794 2 −0.64±0.11 −0.79±0.14 0.3957 4 −0.82±0.13 −0.91±0.13 0.6224 Eye fatigue 1 −0.33±0.12 −0.30±0.10 0.8483 2 −0.48±0.12 −0.39±0.12 0.5923 4 −0.55±0.11 −0.58±0.14 0.8629 Foreign body sensation 1 −0.09±0.13 −0.30±0.14 0.2780 2 −0.36±0.13 −0.33±0.13 0.8683 4 −0.33±0.14 −0.42±0.16 0.6693 Blurred vision 1 0.06±0.07 −0.36±0.10 0.0016 2 0.03±0.07 −0.33±0.15 0.0299 4 −0.21±0.11 −0.48±0.14 0.1321 Eye pain 1 −0.27±0.16 −0.21±0.09 0.7506 2 −0.45±0.16 −0.24±0.12 0.2813 4 −0.48±0.17 −0.33±0.16 0.5258 Photophobia 1 −0.06±0.10 −0.15±0.08 0.4646 2 −0.09±0.09 −0.18±0.11 0.5276 4 −0.18±0.12 −0.21±0.08 0.8359 Heaviness 1 0.00±0.11 −0.24±0.12 0.1277 2 −0.09±0.12 −0.24±0.14 0.4199 4 −0.39±0.11 −0.52±0.14 0.5025 Itching 1 −0.06±0.10 −0.24±0.10 0.1905 2 −0.06±0.10 −0.36±0.12 0.0556 4 −0.21±0.10 −0.36±0.13 0.3652 Ocular discomfort 1 −0.27±0.14 −0.24±0.14 0.8806 2 −0.33±0.10 −0.27±0.14 0.7284 4 −0.42±0.14 −0.55±0.13 0.5369 Eye discharge 1 −0.06±0.04 −0.12±0.10 0.5923 2 −0.09±0.07 −0.27±0.11 0.1600 4 −0.15±0.06 −0.33±0.09 0.1137 Tearing 1 −0.06±0.04 −0.15±0.06 0.2369 2 −0.09±0.07 −0.12±0.07 0.7593 4 −0.06±0.07 −0.12±0.10 0.6384 Hyperemia 1 0.00±0.06 −0.06±0.12 0.6602 2 −0.06±0.10 −0.03±0.13 0.8551 4 −0.21±0.10 −0.12±0.12 0.5719 Total score of the subjective symptoms 1 −0.82±0.32 −1.76±0.30 0.0351 2 −1.52±0.31 −1.88±0.39 0.4695 4 −2.03±0.44 −2.36±0.45 0.5983 Abbreviation: VApal, retinol palmitate. The authors have advised there are some mistakes in the mean changes and standard errors of the paper: 1. The standard errors of groups Placebo and VApal were all the same value for staining and symptom scores in Figure 1 (on page 1875) and Figure 3 (on page 1876), and Table 3 (on page 1877). 2. There were slight discrepancies in the Mean changes of Placebo group at 1, 2 and 4 weeks in Figure 3D. 3. There was a slight discrepancy in the Mean change of foreign body sensation in Placebo group at 1 week in Table 3. The authors have advised the errors were due to: 1. The standard error listed in a different table on the statistical analysis software was adopted. 2. There were typing errors when transferring numerical values from statistical analysis software to graph creation software. 3. There was a mistake when rounding numerical value. Since the statistical analysis had been performed using the original mean values (correct values), all results do not change.  The authors apologize for these errors and advise they do not affect the results of the paper. The updated Figures and Table are shown below. Figure 1 Mean change in staining score. Notes: Mean change in fluorescein staining score (A) and RB staining score (B) from baseline to 1, 2, and 4 weeks. *P<0.05. **P<0.01 versus placebo (unpaired t-test). Abbreviations: RB, rose bengal; VApal, retinol palmitate. Figure 3 Mean change in symptom score. Notes: Mean change in symptom scores for dryness (A), blurred vision (B), heaviness (C), itching (D), and eye discharge (E) and total score for subjective symptoms (F) from baseline to 1, 2, and 4 weeks. *P<0.05. **P<0.01 versus placebo (unpaired t-test). Abbreviation: VApal, retinol palmitate.

          Related collections

          Author and article information

          Journal
          Drug Des Devel Ther
          Drug Des Devel Ther
          dddt
          dddt
          Drug Design, Development and Therapy
          Dove
          1177-8881
          24 February 2021
          2021
          24 February 2021
          : 15
          : 813-816
          Article
          301482
          10.2147/DDDT.S301482
          7917363
          © 2021 Toshida et al.

          This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

          Page count
          Figures: 2, Tables: 1, Pages: 4
          Categories
          Corrigendum

          Pharmacology & Pharmaceutical medicine

          Comments

          Comment on this article